JP2025509507A5 - - Google Patents

Info

Publication number
JP2025509507A5
JP2025509507A5 JP2024554630A JP2024554630A JP2025509507A5 JP 2025509507 A5 JP2025509507 A5 JP 2025509507A5 JP 2024554630 A JP2024554630 A JP 2024554630A JP 2024554630 A JP2024554630 A JP 2024554630A JP 2025509507 A5 JP2025509507 A5 JP 2025509507A5
Authority
JP
Japan
Prior art keywords
optionally substituted
pharmaceutically acceptable
acceptable salt
formula
substituted alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509507A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064416 external-priority patent/WO2023178167A1/en
Publication of JP2025509507A publication Critical patent/JP2025509507A/ja
Publication of JP2025509507A5 publication Critical patent/JP2025509507A5/ja
Pending legal-status Critical Current

Links

JP2024554630A 2022-03-16 2023-03-15 非対称ピペラジン系カチオン性脂質 Pending JP2025509507A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320503P 2022-03-16 2022-03-16
US63/320,503 2022-03-16
PCT/US2023/064416 WO2023178167A1 (en) 2022-03-16 2023-03-15 Asymmetric piperazine-based cationic lipids

Publications (2)

Publication Number Publication Date
JP2025509507A JP2025509507A (ja) 2025-04-11
JP2025509507A5 true JP2025509507A5 (cg-RX-API-DMAC7.html) 2026-03-26

Family

ID=85979858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554630A Pending JP2025509507A (ja) 2022-03-16 2023-03-15 非対称ピペラジン系カチオン性脂質

Country Status (6)

Country Link
US (1) US20260021055A1 (cg-RX-API-DMAC7.html)
EP (1) EP4493548A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509507A (cg-RX-API-DMAC7.html)
CN (1) CN118922409A (cg-RX-API-DMAC7.html)
TW (1) TW202345835A (cg-RX-API-DMAC7.html)
WO (1) WO2023178167A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US12599560B2 (en) 2023-11-02 2026-04-14 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025091377A1 (en) * 2023-11-02 2025-05-08 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025250906A1 (en) 2024-05-30 2025-12-04 Aera Therapeutics, Inc. Process for preparation of targeted lipid nanoparticles
WO2026139004A1 (en) * 2024-12-27 2026-07-02 Suzhou Abogen Biosciences Co., Ltd. Polyglycerol conjugated lipid compounds and lipid nanoparticle compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
RS64331B1 (sr) * 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
US20180153822A1 (en) 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
WO2020227085A1 (en) * 2019-05-03 2020-11-12 Translate Bio, Inc. Di-thioester cationic lipids
WO2021226468A1 (en) * 2020-05-07 2021-11-11 Translate Bio, Inc. Improved compositions for cftr mrna therapy
WO2022066916A1 (en) * 2020-09-23 2022-03-31 Translate Bio, Inc. Piperazine-based cationic lipids

Similar Documents

Publication Publication Date Title
JP2023542944A5 (cg-RX-API-DMAC7.html)
JP2022520061A5 (cg-RX-API-DMAC7.html)
JP2018519818A5 (cg-RX-API-DMAC7.html)
ES2887042T3 (es) Moduladores del receptor S1P para el tratamiento de la esclerosis múltiple
JP2023520047A5 (cg-RX-API-DMAC7.html)
JP2018070614A5 (cg-RX-API-DMAC7.html)
JP2017536092A5 (cg-RX-API-DMAC7.html)
JP2020505403A5 (cg-RX-API-DMAC7.html)
CA2499622A1 (en) Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
JP2022548155A5 (cg-RX-API-DMAC7.html)
JP2001247459A5 (cg-RX-API-DMAC7.html)
JP2022530637A5 (cg-RX-API-DMAC7.html)
JP2005504053A5 (cg-RX-API-DMAC7.html)
JP2021534160A5 (cg-RX-API-DMAC7.html)
JP2024546095A5 (cg-RX-API-DMAC7.html)
US8877236B2 (en) Liposomes active in-vivo on neurodegenerative diseases
US20180022768A1 (en) Radioactive phospholipid metal chelates for cancer imaging and therapy
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
KR20190064573A (ko) 혈액 암 치료용 PPARγ 작용제
JP2021514380A5 (ja) 筋障害及び骨障害を処置するための化合物及び組成物
HUT70213A (en) Antiemetic pharmateutilal preparations
JP2003507434A (ja) 関節症、関節炎、及び他のリウマチ性関節疾患を治療するための医療用調製物
JP6370801B2 (ja) 肝疾患または肝障害の治療のための使用および方法
JP2018529747A5 (cg-RX-API-DMAC7.html)
JP2025512049A5 (cg-RX-API-DMAC7.html)